Use of purified fibrinogen concentrate for dysfibrinogenemia and importance of laboratory fibrinogen activity measurement. Pediatr Blood Cancer 2013 Mar;60(3):500-2
Date
11/07/2012Pubmed ID
23129109Pubmed Central ID
PMC4461026DOI
10.1002/pbc.24383Scopus ID
2-s2.0-84872441623 (requires institutional sign-in at Scopus site) 6 CitationsAbstract
We report a patient with dysfibrinogenemia treated with purified fibrinogen concentrate who had discrepant post-treatment laboratory values. The patient had mild bleeding symptoms and was diagnosed with dysfibrinogenemia based on fibrinogen activity of 51 mg/dl and antigen of 240 mg/dl. He was treated for an adenoidectomy with purified fibrinogen concentrate (RiaSTAP®) at a dose of 70 mg/kg. A discrepancy in post-treatment fibrinogen activity was observed between the hospital and reference laboratories. Investigation revealed differences in laboratory assay and calibration methods. Fibrinogen concentrate may be a treatment option for patients with dysfibrinogenemia, but accurate laboratory technique is critical for fibrinogen measurement.
Author List
Franzblau EB, Punzalan RC, Friedman KD, Roy A, Bilen O, Flood VHAuthors
Veronica H. Flood MD Interim Chief, Professor in the Pediatrics department at Medical College of WisconsinKenneth D. Friedman MD Professor in the Medicine department at Medical College of Wisconsin
Rowena C. Punzalan MD Associate Professor in the Pediatrics department at Medical College of Wisconsin
MESH terms used to index this publication - Major topics in bold
AdolescentAfibrinogenemia
Fibrinogen
Hematologic Tests
Humans
Laboratories
Laboratories, Hospital
Male
